New Hope for Alopecia Areata: Targeting Immune Cells, Exploring COVID-19 Links
Alopecia areata, a condition affecting one in fifty people, causes round, coin-sized bald patches on the scalp. In some cases, it can lead to total hair loss, impacting the scalp, eyebrows, and body hair. Recent research has shed light on potential treatments, including targeting specific immune cells and exploring COVID-19 links.
Alopecia areata, an autoimmune disorder, leads to hair loss in patches, which can merge together. It can also affect eyebrows, eyelashes, and body hair. Researchers have discovered that CD8+ T-cells play a significant role in relapses, directly attacking hair follicles and causing inflammation. Targeting these cells could prevent future hair loss.
Interestingly, COVID-19 might trigger Alopecia areata in some individuals due to shared immune pathways. This connection opens avenues for potential treatments like Alemtuzumab and Bertilimumab, which modulate these immune mechanisms. Additionally, JAK inhibitors such as Baricitinib have been studied, showing promise in treating Alopecia areata without increasing blood clotting risk.
Alopecia areata, affecting one in fifty people, can cause extensive hair loss. Recent findings highlight the role of CD8+ T-cells in relapses and the potential link with COVID-19. Promising treatments targeting these immune cells and pathways are being explored, offering hope for those living with this condition.
